Viracta is committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.
Viracta’s proprietary platform is a highly targeted combination therapy approach for virus-associated malignancies. Our initial focus is on cancers associated with the Epstein Barr Virus (EBV). We will also expand into additional applications to utilize this approach for a range of cancers and viru...
Viracta is committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.
Viracta’s proprietary platform is a highly targeted combination therapy approach for virus-associated malignancies. Our initial focus is on cancers associated with the Epstein Barr Virus (EBV). We will also expand into additional applications to utilize this approach for a range of cancers and virus-associated diseases.
Our team possesses deep, cross-functional experience and longstanding commitment to develop new medicines to benefit patients.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.